ATLAb™ - Antibody Evolution
Scientists at BioAtla have developed an antibody evolution technology platform 
called ATLAb™ Evolution. It combines comprehensive mutagenesis, shuffling and synthesis technologies to enhance single or multiple antibody properties and binding characteristics. BioAtla’s comprehensive mutagenesis technology rapidly generates antibody variants by testing amino acids at every position along an antibody domain’s sequence.
In addition, BioAtla’s combinatorial protein synthesis technologies are able to optimize the desired characteristics of antibodies by combining their best properties into a new, high-performance antibody. The combination of these technologies significantly expands the pool of antibody variants available to be screened and it significantly increases the probability of finding antibodies with single or multiple enhanced characteristics such as binding affinity, specificity, thermo-stability, expression level, effector function, glycosylation, and solubility. We work with our clients to develop and implement appropriate assays to screen for the ideal antibody candidates.